Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. 4 Ağustos 2026 tarihinde ne bildirdi

Şirketin kendi 8-K belgesinden.

Kazanç çağrıları

Odyssey Therapeutics, Inc. için kazanç çağrısı dökümü mevcut değil.

Yönetim ne dedi

“Positive clinical proof-of-concept data for OD-001 marked an important milestone for Odyssey and we look forward to sharing additional, supportive data from this trial in October,”

Açıklamadan birebir alıntılanmıştır ve yalnızca belge sözü adı geçen bir kişiye atfettiğinde gösterilir.

Fiyat nasıl tepki verdi

Açıklamalar kapanıştan sonra ya da açılıştan önce gelir, dolayısıyla hareket bir sonraki seansa aittir.

Odyssey Therapeutics, Inc. ne yapar

Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.

Şirketin kendi tanımı, açıklamanın sonunda göründüğü hâliyle.